CCR2 and head and neck squamous cell carcinoma: Notably, combining the CCR2 chemokine receptor antagonist RS504393 with IL6 blockade resulted in a more pronounced antitumor effect, characterized by more activated intratumoral NK cells in HPV-negative HNSCC compared to either agent alone.